Adaptive R&D contract for urgently needed drugs: Lessons from COVID-19 vaccine development
DC Field | Value | Language |
---|---|---|
dc.contributor.author | (Ryan), Choi,J.-H. | - |
dc.contributor.author | Yoon, Ji Ho | - |
dc.contributor.author | Song, J.M. | - |
dc.date.accessioned | 2023-03-08T04:48:04Z | - |
dc.date.available | 2023-03-08T04:48:04Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0305-0483 | - |
dc.identifier.issn | 1873-5274 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61118 | - |
dc.description.abstract | This paper analyzes an incentive contract for new vaccine research and development (R&D) under pandemic situations such as COVID-19, considering the R&D contract's adaptability to the pandemic. We study how the public sector (government) designs the adaptive R&D contract and offers it to pharmaceutical enterprises. An agency-theoretic model is employed to explore the contract whose terms are an upfront grant as a fixed fee and a sales tax credit as an incentive tool, examining how the values of related parameters affect contract term determinations. We found that the adaptability factor derived from urgent policies such as emergency use authorization (EUA) as well as tax credits, can be utilized as practical incentive tools that lead vaccine developers to increase their effort levels for R&D success. We also found that public-private state-emergency contracts may not follow the conventional wisdom. Counterintuitively, dependency on tax credits (incentive part) decrease as the client's degree of risk averseness increases in the emergency contract. © 2022 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Ltd | - |
dc.title | Adaptive R&D contract for urgently needed drugs: Lessons from COVID-19 vaccine development | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.omega.2022.102727 | - |
dc.identifier.bibliographicCitation | Omega (United Kingdom), v.114 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000874774300006 | - |
dc.identifier.scopusid | 2-s2.0-85136013423 | - |
dc.citation.title | Omega (United Kingdom) | - |
dc.citation.volume | 114 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Adaptive R&D contract | - |
dc.subject.keywordAuthor | Agency theory | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Incentive tools | - |
dc.subject.keywordAuthor | Tax credit | - |
dc.subject.keywordPlus | PRODUCT | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordPlus | IMPACT | - |
dc.relation.journalResearchArea | Business & Economics | - |
dc.relation.journalResearchArea | Operations Research & Management Science | - |
dc.relation.journalWebOfScienceCategory | Management | - |
dc.relation.journalWebOfScienceCategory | Operations Research & Management Science | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.